TY - JOUR
T1 - Advances in CRISPR-Cas9 genome engineering
T2 - Lessons learned from RNA interference
AU - Barrangou, Rodolphe
AU - Birmingham, Amanda
AU - Wiemann, Stefan
AU - Beijersbergen, Roderick L.
AU - Hornung, Veit
AU - Smith, Anja Van Brabant
N1 - Publisher Copyright:
© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
PY - 2015/3/5
Y1 - 2015/3/5
N2 - The discovery that the machinery of the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 bacterial immune system can be re-purposed to easily create deletions, insertions and replacements in the mammalian genome has revolutionized the field of genome engineering and re-invigorated the field of gene therapy. Many parallels have been drawn between the newly discovered CRISPR-Cas9 system and the RNA interference (RNAi) pathway in terms of their utility for understanding and interrogating gene function in mammalian cells. Given this similarity, the CRISPR-Cas9 field stands to benefit immensely from lessons learned during the development of RNAi technology. We examine how the history of RNAi can inform today's challenges in CRISPR-Cas9 genome engineering such as efficiency, specificity, high-throughput screening and delivery for in vivo and therapeutic applications.
AB - The discovery that the machinery of the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 bacterial immune system can be re-purposed to easily create deletions, insertions and replacements in the mammalian genome has revolutionized the field of genome engineering and re-invigorated the field of gene therapy. Many parallels have been drawn between the newly discovered CRISPR-Cas9 system and the RNA interference (RNAi) pathway in terms of their utility for understanding and interrogating gene function in mammalian cells. Given this similarity, the CRISPR-Cas9 field stands to benefit immensely from lessons learned during the development of RNAi technology. We examine how the history of RNAi can inform today's challenges in CRISPR-Cas9 genome engineering such as efficiency, specificity, high-throughput screening and delivery for in vivo and therapeutic applications.
UR - http://www.scopus.com/inward/record.url?scp=84930503842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930503842&partnerID=8YFLogxK
U2 - 10.1093/nar/gkv226
DO - 10.1093/nar/gkv226
M3 - Review article
C2 - 25800748
AN - SCOPUS:84930503842
SN - 0305-1048
VL - 43
SP - 3407
EP - 3419
JO - Nucleic Acids Research
JF - Nucleic Acids Research
IS - 7
ER -